GlassScriptPhysician profile
Danny P Mathew
NPI 1578753323
$5,740.29
in general payments reported to CMS, 2019-2025
24 companies · $768 in 2025
The $768 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $202 · 2021: $416 · 2022: $777 · 2023: $701 · 2024: $569 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,775.08 | 2019-2025 | Dailies Total1, Rocklatan, Total30 |
| Bausch & Lomb Americas INC. | $654.27 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Biotissue Holdings INC. | $423.84 | 2019-2025 | |
| Sight Sciences, INC. | $325.62 | 2019-2025 | Tearcare System, Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $235.53 | 2019-2021 | |
| Abbvie INC. | $219.81 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $219.30 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $162.86 | 2021 | |
| Glaukos Corporation | $140.66 | 2022 | |
| Dompe US, INC. | $104.23 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $52.84 | 2023 | Tepezza |
| Optos, INC. | $49.36 | 2022 | |
| Rayner Intraocular Lenses Limited | $49.21 | 2024-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Eyepoint US, INC. | $46.26 | 2019-2020 | |
| Ocular Therapeutix, INC. | $44.36 | 2025 | Dextenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $38.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.77 | 2019-2021 | |
| Coopervision INC. | $28.34 | 2023 | Misight Contact Lens, Myday Contact Lens |
| Oyster Point Pharma, INC. | $27.29 | 2022 | |
| Rxsight INC | $24.36 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Harrow Eye, LLC | $23.61 | 2023 | Vevye |
| Johnson & Johnson Vision Care, INC. | $22.34 | 2019 | |
| Shire North American Group INC | $18.70 | 2019 | |
| Allergan, INC. | $16.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.